NCT04856189View on ClinicalTrials.gov

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 8, 2021

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions
Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaRefractory Urothelial Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Selinexor

Given PO

Trial Locations (1)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

Karyopharm Therapeutics Inc

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Mamta Parikh

OTHER